Metastatic Colorectal Cancer Market

DelveInsight’s ‘Metastatic Colorectal Cancer (mCRC) Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The mCRC market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM mCRC market size from 2017 to 2030. The report also covers current mCRC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2017–2030


Metastatic Colorectal Cancer (mCRC) Disease Understanding and Treatment Algorithm

Metastatic Colorectal Cancer (mCRC) Overview

Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped together because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.


CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer is the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC.


Generally, most CRCs (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one’s children. Inherited CRCs are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of CRC is not known.


Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is.

If cancer forms in a polyp, it can grow into the wall of the colon or rectum over time. The wall of the colon and rectum is made up of many layers. CRC starts in the innermost layer (the mucosa) and can grow outward through some or all of the other layers. When cancer cells are in the wall, they can then grow into blood vessels or lymph vessels (tiny channels that carry away waste and fluid). From there, they can travel to nearby lymph nodes or distant parts of the body. The stage (extent of spread) of a CRC depends on how deeply it grows into the wall and if it has spread outside the colon or rectum.


Metastatic Colorectal Cancer (mCRC) Diagnosis

Approximately one-fifth of CRC cases are metastatic at the time of diagnosis. Patients can present with a wide range of signs and symptoms such as occult or overt rectal bleeding, change in bowel habits, anemia, or abdominal pain. However, CRC is largely an asymptomatic disease until it reaches an advanced stage. By contrast, rectal bleeding is a common symptom of both benign and malignant causes. Therefore additional risk factors might be needed to help identify those people who should undergo further investigation by colonoscopy. New-onset rectal bleeding should generally prompt colonoscopy in individuals aged 45 years or older. In younger patients, additional factors are used to identify those at highest risk for CRC (e.g., having a family history of CRC, change in bowel habits, unexplained weight loss, and blood mixed with the stool as opposed to blood on the surface of the stool).


Metastatic Colorectal Cancer (mCRC) Treatment

Metastatic CRC is still an incurable disease for most of the patients, with most commonly liver, lung or lymph nodes and peritoneal metastases. In the past, 15 years ago, median overall survival (mOS) was approximately 12 months, and the 5-year survival rate was 13%. However, the survival rate of these patients has increased, mainly due to the combined treatment of metastases with surgery and systemic therapy. Long-term survival or even cure can be attained in 20–50% of the patients who undergo complete R0 resection of liver or lung metastases, and around 70% 5-year survival of these patients can be achieved.


However, in the field of systemic therapy, there has been significant progress with new drugs in recent years. There are more options of initial systemic chemotherapy, oxaliplatin, irinotecan, and fluoropyrimidines, in combination with targeted therapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab) in case of KRAS wild type tumors or anti-vascular endothelial growth factor (VEGF) inhibitors (monoclonal antibodies bevacizumab, aflibercept, ramucirumab, regorafenib as per oral tyrosine kinase inhibitor). The combination of these novel chemotherapies and targeted therapy now extends the mOS up to 40 months.


The treatment plan may include a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, which can be used to slow the spread of the disease and often temporarily shrink a cancerous tumor. Palliative care will also be important to help relieve symptoms and side effects. At this stage, surgery to remove the portion of the colon where cancer started usually cannot cure cancer, but it can help relieve the blockage of the colon or other problems related to cancer. Surgery may also be used to remove parts of other organs that contain cancer, called resection, and can cure some people if a limited amount of cancer spreads to a single organ, such as the liver or a lung. If the CRC has spread only to the liver and if surgery is possible—either before or after chemotherapy—there is a chance of complete cure. Even when curing the cancer is not possible, surgery may add months or even years to a person’s life.


Metastatic Colorectal Cancer (mCRC) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Population of Colorectal Cancer, Gender-specific Distribution of Colorectal Cancer, Age-specific Distribution of Colorectal Cancer, Incident Population of Colorectal Cancer based on Tumor Localization, Incident Population of Colorectal Cancer based on CRC Staging and Incident Population of Metastatic Colorectal Cancer (mCRC) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.


Key Findings

This section provides glimpse of the CRC epidemiology in the 7MM.

  • The incident population of CRC in the seven major markets was 518,742 in 2017.
  • The incident population of mCRC in the seven major markets is estimated to be 213,181 in 2020.
  • In the United States, the number of males and females with CRC is estimated to be 89,527 and 63,773, respectively, in 2020.
  • CRC can be divided based upon the tumor localization at the right colon, transverse, left colon, rectosigmoid, and rectum. In the United States, the estimated number of CRC cases with tumor localization at the right colon, transverse, left colon, rectosigmoid, and rectum was 48,751, 19,616, 46,299, 13,558, and 16,298 cases in 2017 .
  • In 2017, CRC incidence, in the United States, was highest in the age group of 65–84 years, followed by 45–64 years and ≥85 years with 64,184, 54,087, and 16,443 cases, respectively. The lowest incidence of CRC was observed in the people below <20 years (433 cases), preceded by the age group 20–44 years (9,087 cases) in 2017.
  • In the EU5 countries, the incidence of mCRC was maximum in Germany with 23,499 cases, followed by the Italy with 20,310 cases in 2017. While, the least number of cases were in Spain, with 15,400 cases in 2017
  • In Japan, the incidence of mCRC is estimated to be 60,482 in 2020.

 

Country-wise Metastatic Colorectal Cancer (mCRC) Epidemiology

The epidemiology segment also provides the Metastatic Colorectal Cancer (mCRC)epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


Metastatic Colorectal Cancer (mCRC) Drug Chapters

The drug chapter segment of the Metastatic Colorectal Cancer (mCRC) report encloses the detailed analysis of Metastatic Colorectal Cancer (mCRC) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Metastatic Colorectal Cancer (mCRC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.


Metastatic Colorectal Cancer (mCRC) Marketed Drugs

Braftovi (encorafenib) + Erbitux (cetuximab)/ Braftovi + Mektovi: Array BioPharma/ Pfizer

Braftovi is an oral small-molecule BRAF kinase inhibitor that targets a key enzyme in the MAPK signaling pathway (RAS-RAF-MEK-ERK). Inappropriate activation of proteins in this pathway has been shown to occur in many cancers, including melanoma, colorectal cancer, and others. While Erbitux is a recombinant, human/mouse chimeric monoclonal antibody. The antibody binds to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha. While Mektovi is an oral small molecule MEK inhibitor that targets key enzymes in the MAPK signaling pathway.

Product details in the report…


Keytruda (pembrolizumab) injection: Merck

Keytruda is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. The drug is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1, and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. There are currently more than 1,200 trials studying Keytruda across a wide variety of cancers and treatment settings. In June 2020, the US FDA approved Keytruda for intravenous injection for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) CRC.

Product details in the report…


Nivolumab (Opdivo) + Ipilimumab (Yervoy): Bristol-Myers Squibb

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. Combined nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) mediated inhibition results in an enhanced T-cell function that is greater than the effects of either antibody alone and results in improved anti-tumor responses in metastatic melanoma and advanced RCC.

Product details in the report…


Cyramza (ramucirumab) injection + FOLFIRI: Eli Lilly

Ramucirumab is a monoclonal antibody, VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGFR2, thereby inhibiting ligand-induced proliferation and migration of human endothelial cells. The drug inhibited angiogenesis in an in vivo animal model. In April 2015 the drug was approved for use in combination with FOLFIRI (leucovorin, fluorouracil, irinotecan) for treatment of patients with mCRC with disease progression on a first-line line regimen including bevacizumab (Avastin), oxaliplatin, and a fluoropyrimidine. The drug was initially approved to treat patients with gastric cancer and, subsequently, to treat non–small cell lung cancer

Product details in the report…


Lonsurf: Taiho Oncology

Lonsurf (trifluridine/tipiracil), discovered and developed by Taiho Pharmaceutical., is an oral anticancer drug, which utilizes the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines. FTD is an antineoplastic nucleoside analogue, which is incorporated directly into the DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase.

Product details in the report…


Vectibix (panitumumab) + Folfox: Amgen

Vectibix is the first fully human anti-EGFR antibody approved by the US Food and Drug Administration (FDA) for the treatment of mCRC.The drug was approved in the US in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing mCRC after disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. In May 2014, the FDA approved Vectibix for use in combination with Folfox, as a first-line treatment in patients with wild-type KRAS (exon 2) mCRC.

Product details in the report…


Metastatic Colorectal Cancer (mCRC) Emerging Drugs

Napabucasin (BBI-608): Sumitomo Dainippon Pharma

Napabucasin is an orally administered small molecule investigational first-in-class anti-cancer agent created by Boston Biomedical, a wholly-owned subsidiary of Sumitomo Dainippon Pharma. The drug is bio-activated by the enzyme NQO1 in cancer cells, which generates reactive oxygen species to inhibit cancer stemness and tumor progression-related pathways, including STAT3, which is expected to result in cancer cell death.

Product details in the report…


Fruquintinib: Hutchison Medipharma Limited

Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1/2/3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. The drug is designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability, and provide more consistent target coverage. The generally good tolerability in patients to date, along with fruquintinib’s low potential for drug-drug interaction based on preclinical assessment, suggests that it may also be highly suitable for combinations with other anti-cancer therapies.

Product details in the report…


Trilaciclib: G1 Therapeutics

Trilaciclib is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy and improve patient outcomes. Various randomized clinical trials have demonstrated that trilaciclib can provide myelopreservation benefits (i.e., reduction of chemotherapy-induced myelosuppression) and, in certain settings, trilaciclib has the potential to improve survival. It is a short-acting CDK4/6 inhibitor that is administered intravenously prior to chemotherapy.

Product details in the report…


Modufolin (arfolitixorin): Isofol Medical

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced CRC. As the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin, arfolitixorin can potentially benefit all patients with advanced CRC, as it does not require complicated metabolic activation to become effective. When treating CRC, arfolitixorin is administered in combination with 5-FU to increase cell mortality in circulating cancer cells and in cancerous tumors. Arfolitixorin is administered in conjunction with rescue therapy after high-dose treatment with the cytotoxic agent, methotrexate, to suppress the cytotoxic effect in surrounding healthy tissue.

Product details in the report…


Olaparib ± Bevacizumab: Merck

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells. Inhibition of PARP with Lynparza leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks, and cancer cell death. Lynparza is being tested in a range of tumor types with defects and dependencies in the DDR.

Product details in the report…


Avelumab + Cetuximab: Merck

Bavencio (avelumab) is a human anti-programmed death ligand-1 (PD-L1) antibody. Bavencio has been shown in preclinical models to engage both the adaptive and innate immune functions. In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize Bavencio. Erbitux (cetuximab) is an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard nonselective chemotherapy treatments in that it specifically targets and binds to the EGFR.

Product details in the report…


Lenvatinib + Pembrolizumab: Merck/Eisai

Lenvima (lenvatinib), discovered and developed by Eisai, is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). However, Keytruda (pembrolizumab) is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. The drug is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands.

Product details in the report…


Tucatinib + Trastuzumab: Merck/Seagen

Tucatinib (Tukysa) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth. HER2 is overexpressed in multiple cancers, including colorectal cancers. The combination of Tukysa and trastuzumab have also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Trastuzumab (Herceptin) is a type of targeted cancer drug called a monoclonal antibody. It works by attaching to HER2, so it stops the cancer cells from growing and dividing

Product details in the report…


Tomivosertib + Avelumab: Effector Therapeutics

Tomivosertib (also known as eFT508) is a novel, potent, and highly selective oral small molecule inhibitor of mitogen-activated protein kinase interacting kinases 1 and 2, or collectively, MNK1/2. MNK1/2 plays a crucial role in the development of many tumors, like controlling in a coordinated manner, the expression of multiple factors that attenuate an immune response. The preclinical and clinical studies suggest combining tomivosertib with a checkpoint inhibitor that can overcome mechanisms of resistance to checkpoint inhibitors, resulting in enhanced sensitivity to checkpoint inhibitors and a higher response rate. Product details in the report…


Metastatic Colorectal Cancer (mCRC) Market Outlook

Colorectal cancer (CRC) is the second most frequent type of cancer that represents approximately 12–14% of all cancer cases in men and women. Out of these, approximately 25% of patients present with metastases at initial diagnosis and almost 50% may eventually develop metastases, contributing to the high mortality rates reported for CRC. In order to identify the optimal treatment strategy for patients with mCRC, tumor staging is essential and should include at least clinical examination, blood counts, liver and renal function tests, CEA, and CT scan of the abdomen and chest (or alternatively MRI).

The treatment plan may include a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, which can be used to slow the spread of the disease and often temporarily shrink a cancerous tumor. Palliative care is also important to help relieve symptoms and side effects.


The first, second, and third-line treatment regimen of mCRC involves the use of multi-agent chemotherapy (i.e. FOLFOX, FOLFIRI, CAPEOX), anti-angiogenesis therapy with or without chemotherapy, epidermal growth factor receptor (EGFR) inhibitors with or without chemotherapy, and others with or without chemotherapy. Along with these therapies, Opdivo, with or without Yervoy, and Braftovi, in combination with Erbitux, are approved for the treatment of mCRC patients as the only second and third-line therapies, while Keytruda is approved as the only first-line therapy of mCRC.

The backbone of first-line palliative chemotherapy alone, as well in combination with targeted agents, is comprised of a fluoropyrimidine (FP) (intravenous 5-fluorouracil [5-FU] or the oral FP capecitabine) in various combinations and schedules. Of these, the oral FP capecitabine is considered as an alternative to intravenous infusion 5-FU/LV. Anti-angiogenesis therapy is focused on stopping angiogenesis, which is the process of making new blood vessels. This class of therapy involves bevacizumab (Avastin), regorafenib (Stivarga), Ziv-aflibercept (Zaltrap), and ramucirumab (Cyramza). Either of these drugs can be combined with FOLFIRI chemotherapy as a second-line treatment for mCRC. On the other hand, drugs that block EGFR may also be effective for stopping or slowing the growth of CRC. Most commonly used EGFR inhibitors for treating mCRC patients include cetuximab (Erbitux) and Panitumumab (Vectibix). Besides these therapies, Keytruda, Opdivo with or without Yervoy, and Braftovi in combination with Erbitux comprise the most recent approvals seen by the mCRC market.


The pipeline of mCRC holds potential Phase III products by key players, such as Hutchison Medipharma (fruquintinib), Isofol Medical (arfolitixorin), Sumitomo Dainippon Pharma (napabucasin/BBI-608), G1 Therapeutics (trilaciclib + Chemotherapy), Merck (Olaparib ± Bevacizumab) and AB Science (masitinib + Chemotherapy).


Besides these therapies, several key players are investigating their products in mid and early phases of development (Phase II and I/II), namely, Pfizer (Braftovi [encorafinib] + Mektovi [binimetinib] + Erbitux [cetuximab]), Daiichi Sankyo/Astrazeneca (DS-8201a/ ENHERTU), Merck/ Eisai (Lenvima [MK-7902] + Keytruda), Merck/ Seagen (Trastuzumab + Tucatinib [TUKYSA]), Effector Therapeutics (Tomivosertib [eFT508] ± Avelumab), Exelixis (Cabozantinib), Mirati Therapeutics (Adagrasib ± Cetuximab), Merck (Avelumab + Cetuximab ± FOLFOX), Cardiff Oncology (Onvansertib), and NOXXON Pharma (NOX-A12 + pembrolizumab).


Key Findings

This section includes a glimpse of the mCRC 7MM market.


  • The market size of mCRC in the seven major markets is estimated to be USD 12,682 Million in 2020.
  • The United States accounts for the largest market size of mCRC in comparison to EU5 (the United Kingdom, Germany, France, Italy, and Spain) and Japan.
  • Among the EU5 countries, Germany had the highest market size with USD 1,084.0 Million in 2017, while Spain had the smallest market size of mCRC with USD 710.4 Million in 2017, which is expected to rise during the study period 2017–2030.
  • The Japan mCRC market is estimated to account for USD 2,824.5 Million in 2020.


The United States Market Outlook

This section provides the total Metastatic Colorectal Cancer (mCRC) market size and market size by therapies in the United States.


EU-5 Market Outlook

The total Metastatic Colorectal Cancer (mCRC) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Metastatic Colorectal Cancer (mCRC) market size and market size by therapies in Japan are provided.


Metastatic Colorectal Cancer (mCRC) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Metastatic Colorectal Cancer (mCRC) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Metastatic Colorectal Cancer (mCRC) market uptake by drugs; patient uptake by therapies; and sales of each drug.  

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Metastatic Colorectal Cancer (mCRC) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Metastatic Colorectal Cancer (mCRC) emerging therapies.


Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Metastatic Colorectal Cancer (mCRC) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.


Scope of the Report

  • The report covers the descriptive overview of Metastatic Colorectal Cancer (mCRC), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Metastatic Colorectal Cancer (mCRC) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Metastatic Colorectal Cancer (mCRC) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Metastatic Colorectal Cancer (mCRC) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Metastatic Colorectal Cancer (mCRC) market.


Report Highlights

  • In the coming years, mCRC market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence mCRC R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Delvelnsight analysed gender-specific data of mCRC, which suggests that the incidence of mCRC is more frequent in males than in females.
  • Delvelnsight has also analysed data on types of CRC based on CRC staging, which suggests that localized CRC was the most common type of CRC, followed by regional type.
  • CRC can also be divided based upon the tumor localization at the right colon, transverse, left colon, rectosigmoid, and rectum. As per Delvelnsight’s analysis, the maximum number of incident cases of CRC are found at the right colon followed by the left colon.
  • Age-specific data of CRC suggests that incidence of CRC in the US, was highest in the age group of 65–84 years, followed by 45–64 years and ≥85 years.
  • Currently, the first, second and third-line treatment regimen of mCRC involves the use of Multiagent Chemotherapy (i.e. Folfox, Folfiri, Capeox), Anti-angiogenesis therapy with or without Chemotherapy, Epidermal growth factor receptor (EGFR) inhibitors with or without Chemotherapy, Keytruda, Opdivo with or without Yervoy, Braftovi in combination with Erbitux and Others with Chemotherapy.
  • Expected Launch of potential therapies, Napabucasin/ BBI-608 (Sumitomo Dainippon Pharma), Fruquintinib (Hutchison Medipharma), Arfolitixorin/ Modufolin (Isofol Medical), Trilaciclib + Chemotherapy (G1 Therapeutics), Olaparib ± Bevacizumab (Merck), Masitinib + Chemotherapy (AB Science), Braftovi/ encorafinib ± Mektovi/ binimetinib + Erbitux/ cetuximab (Pfizer), DS-8201a/ Enhertu (Daiichi Sankyo/ Astrazeneca), Lenvima/ MK-7902 + Keytruda (Merck/ Eisai), Trastuzumab + Tucatinib/ Tukysa (Merck/ Seagen), Tomivosertib/ eFT508 ± Avelumab (Effector Therapeutics), Cabozantinib (Exelixis), Adagrasib ± Cetuximab (Mirati Therapeutics), Avelumab + Cetuximab (Merck), Avelumab + Cetuximab ± Folfox (Merck), Onvansertib (Cardiff Oncology) and NOX-A12 + pembrolizumab (Noxxon Pharma), may increase the market size in the coming years, assisted by an increase in the incident population of mCRC.


Metastatic Colorectal Cancer (mCRC) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Metastatic Colorectal Cancer (mCRC) Pipeline Analysis
  • Metastatic Colorectal Cancer (mCRC) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Metastatic Colorectal Cancer (mCRC) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Metastatic Colorectal Cancer (mCRC)Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake


Metastatic Colorectal Cancer (mCRC) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Metastatic Colorectal Cancer (mCRC) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Metastatic Colorectal Cancer (mCRC) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Metastatic Colorectal Cancer (mCRC)market size during the forecast period (2020–2030)?
  • At what CAGR, the Metastatic Colorectal Cancer (mCRC) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
  • What would be the Metastatic Colorectal Cancer (mCRC) market outlook across the 7MM during the forecast period (2020–2030)?
  • What would be the Metastatic Colorectal Cancer (mCRC) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Metastatic Colorectal Cancer (mCRC)?
  • What is the historical Metastatic Colorectal Cancer (mCRC) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Metastatic Colorectal Cancer (mCRC) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Metastatic Colorectal Cancer (mCRC)?
  • Out of the above-mentioned countries, which country would have the highest incident population of Metastatic Colorectal Cancer (mCRC)during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?


Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Metastatic Colorectal Cancer (mCRC) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Metastatic Colorectal Cancer (mCRC) in the US and Europe?
  • What are the Metastatic Colorectal Cancer (mCRC) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Metastatic Colorectal Cancer (mCRC)?
  • How many therapies are developed by each company for the treatment of Metastatic Colorectal Cancer (mCRC)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Metastatic Colorectal Cancer (mCRC)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Colorectal Cancer (mCRC) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Metastatic Colorectal Cancer (mCRC) and their status?
  • What are the key designations that have been granted for the emerging therapies for Metastatic Colorectal Cancer (mCRC)?
  • What are the 7MM historical and forecasted market of Metastatic Colorectal Cancer (mCRC)?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Metastatic Colorectal Cancer (mCRC).
  • To understand the future market competition in the Metastatic Colorectal Cancer (mCRC) market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Metastatic Colorectal Cancer (mCRC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Metastatic Colorectal Cancer (mCRC) market.
  • To understand the future market competition in the Metastatic Colorectal Cancer (mCRC) market.

1 Key Insight

2 Executive Summary

3 Metastatic Colorectal Cancer (mCRC) Market Overview At A Glance

3.1 Market Share (%) Distribution Of Metastatic Colorectal Cancer (mCRC) In 2017

3.2 Market Share (%) Distribution Of Metastatic Colorectal Cancer (mCRC) In 2030

4 Disease Background And Overview: Metastatic Colorectal Cancer (mCRC)

4.1 Introduction

4.2 Causes

4.3 Symptoms

4.4 CRC Staging

4.5 Risk Factors Of CRC

4.6 Molecular Subtypes Of CRC

4.7 Mechanisms Of Metastasis In CRC

4.8 Drug Resistance In mCRC

4.9 Clinical Presentation Of mCRC

4.10 Unusual Sites Of Metastasis In CRC

4.10.1 Uterine Metastasis

4.10.2 Penile Metastasis

4.10.3 Scrotal Metastasis

4.10.4 Prostatic Metastasis

4.10.5 Bladder Metastasis

4.10.6 Peritoneal Pseudomyxoma

4.10.7 Abdominal Wall Metastasis

4.10.8 Bone Metastasis

4.10.9 Carcinomatous Lymphangitis

4.10.10 Adenopathies

4.10.11 Pancreatic Metastasis

4.11 Biomarkers In mCRC

4.11.1 Prognostic Biomarkers

4.11.2 Patient-Related Factors

4.11.3 Tumor-related Factors

4.11.4 Predictive Biomarkers

4.11.5 Markers to Predict 5-FU Response and Toxicity

4.11.6 Predicting Response to EGFR Therapy

4.11.7 Predicting Response to VEGF Inhibitors

4.11.8 Technology-Facilitated Biomarkers

4.12 Diagnosis

4.12.1 Clinical symptoms

4.12.2 Endoscopy

4.12.3 Imaging

4.12.4 Laboratory

4.12.5 Pathology

4.12.6 Biopsy

4.12.7 Molecular Testing of the Tumor

4.12.8 Blood Tests

4.12.9 Tumor-based Tests

4.12.10 Diagnosis of colorectal liver metastasis

5 Recognized Establishments

6 Treatment of Metastatic Colorectal Cancer (mCRC)

6.1 Initial/ First-line Treatment Of mCRC

6.2 Second And Third-line Treatment Of mCRC

6.3 Therapies Using Medication

6.4 Surgery

6.5 Adjuvant Therapy

6.6 Follow-up

6.7 Palliation

6.8 Maintenance Therapy

6.9 Treatment Of Colon Cancer That Has Metastasized To A Single Site

7 Treatment Of Patients With Late-stage Colorectal Cancer: ASCO Resource-stratified Guideline (2020)

8 Esmo Consensus Guidelines For The Management Of Patients With Metastatic Colorectal Cancer (2016)

8.1.1 Recommendation 1: Tissue Handling

8.1.2 Recommendation 2: A Selection Of Specimens For Biomarker Testing

8.1.3 Recommendation 3: Tissue Selection

8.1.4 Recommendation 4: RAS Testing

8.1.5 Recommendation 5: BRAF Testing

8.1.6 Recommendation 6: MSI Testing

8.1.7 Recommendation 7: Biomarkers Of Chemotherapy Sensitivity And Toxicity

8.1.8 Recommendation 8: Emerging Biomarkers Not Recommended For Routine Patient Management Outside Of A Clinical Trial Setting

8.1.9 Recommendation 9: Emerging Technologies

8.1.10 Recommendation 10: OMD

8.1.11 Recommendation 11: Imaging In The Identification And Management Of Disease

8.1.12 Recommendation 12: Perioperative Treatment

8.1.13 Recommendation 13: Conversion Therapy

8.1.14 Recommendation 14: Ablative Techniques

8.1.15 Recommendation 15: Local Ablation Techniques

8.1.16 Recommendation 16: Embolization

8.1.17 Recommendation 17: Cytoreductive Surgery And HIPEC

8.1.18 Recommendation 18: First-line Systemic Therapy Combinations According To The Targeted Agent Used

8.1.19 Recommendation 19: Maintenance Therapy

8.1.20 Recommendation 20: Second-line Combinations With Targeted Agents

8.1.21 Recommendation 21: Third-line Therapy

8.2 Consensus Recommendations On The Use Of Cytotoxics And Biologicals In The First- And Subsequent-line Treatment Of Patients With Mcrc

8.2.1 Consensus Recommendation For Patients Where Cytoreduction With 'conversion' And/Or The Integration Of Local Ablative Treatment Is The Goal

8.2.2 Consensus Recommendation For Patients Where Cytoreduction Is Needed Because Of Aggressive Biology And/Or Risk Of Developing Or Existing Severe Symptoms

8.2.3 Consensus Recommendation For Patients Where Disease Control Is The Goal

9 National Institute For Health And Care Excellence (NICE) Guidelines: Colorectal Cancer (Updated 2020)

9.1 Management Of Metastatic Disease

9.1.1 People with asymptomatic primary tumor

9.1.2 People with mCRC in the liver

9.1.3 People with metastatic colorectal cancer in the lung

9.1.4 People with metastatic colorectal cancer in the peritoneum

9.2 Ongoing Care And Support

9.2.1 Follow-up for detection of local recurrence and distant metastases

10 Management Of Metastatic Colorectal Cancer Patients: Guidelines Of The Italian Medical Oncology Association (AIOM) (2016)

10.1 mCRC Treatment Recommendations

10.1.1 Evaluation Of Elderly Patients

10.1.2 Surgery For Advanced Disease

10.1.3 Locoregional Treatments

11 Treatment Guidelines Of Metastatic Colorectal Cancer In Older Patients From The French Society Of Geriatric Oncology (SOFOG)

11.1 Recommendations On Palliative Chemotherapy Indication For Older Patients With mCRC

11.2 Recommendations For Cytotoxic Chemotherapy In Older Patients:

11.3 Anti-angiogenic Recommendations For Older:

11.4 Recommendations For Anti-EGFR, Regorafenib And Trifluridinetipiracil In Older Patients

12 Spanish Society Of Medical Oncology (SEOM) Clinical Guidelines For Diagnosis And Treatment Of Metastatic Colorectal Cancer (2018)

13 Japanese Society For Cancer Of The Colon And Rectum (JSCCR) Guidelines 2019 For The Treatment Of Colorectal Cancer

13.1 Treatment Strategies For Stage IV CRC

13.2 Treatment Strategies For Hematogenous Metastases

13.2.1 Treatment Strategies For Liver Metastases

13.2.2 Treatment Strategies For Brain Metastases

13.2.3 Treatment Strategies For Hematogenous Metastases To Other Organs

14 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines For Colon And Rectal Cancer (2020)

15 Treatment Algorithm

16 Epidemiology And Patient Population

16.1 Key Findings

16.2 7MM Incident Population Of Colorectal Cancer

16.3 7MM Incident Population Of Metastatic Colorectal Cancer

17 7MM Epidemiology Of Metastatic Colorectal Cancer

17.1 Assumptions And Rationale

17.2 United States

17.2.1 Incident Cases of Colorectal Cancer in the United States

17.2.2 Gender-specific Distribution of Colorectal Cancer in the United States

17.2.3 Age-specific Distribution of Colorectal Cancer in the United States

17.2.5 Incident Cases of Colorectal Cancer based on Tumor Localization in the United States

17.2.6 Incident Cases of Colorectal Cancer based on CRC Staging in the United States

17.2.7 Incident Cases of Metastatic Colorectal Cancer in the United States

17.3 EU5 Countries

17.4 Germany

17.4.1 Incident Cases of Colorectal Cancer in Germany

17.4.2 Gender-specific Distribution of Colorectal Cancer in Germany

17.4.3 Age-specific Distribution of Colorectal Cancer in Germany

17.4.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Germany

17.4.6 Incident Cases of Colorectal Cancer based on CRC Staging in Germany

17.4.7 Incident Cases of Metastatic Colorectal Cancer in Germany

17.5 France

17.5.1 Incident Cases of Colorectal Cancer in France

17.5.2 Gender-specific Distribution of Colorectal Cancer in France

17.5.3 Age-specific Distribution of Colorectal Cancer in France

17.5.5 Incident Cases of Colorectal Cancer based on Tumor Localization in France

17.5.6 Incident Cases of Colorectal Cancer based on CRC Staging in France

17.5.7 Incident Cases of Metastatic Colorectal Cancer in France

17.6 Italy

17.6.1 Incident Cases of Colorectal Cancer in Italy

17.6.2 Gender-specific Distribution of Colorectal Cancer in Italy

17.6.3 Age-specific Distribution of Colorectal Cancer in Italy

17.6.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Italy

17.6.6 Incident Cases of Colorectal Cancer based on CRC Staging in Italy

17.6.7 Incident Cases of Metastatic Colorectal Cancer in Italy

17.7 Spain

17.7.1 Incident Cases of Colorectal Cancer in Spain

17.7.2 Gender-specific Distribution of Colorectal Cancer in Spain

17.7.3 Age-specific Distribution of Colorectal Cancer in Spain

17.7.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Spain

17.7.6 Incident Cases of Colorectal Cancer based on CRC Staging in Spain

17.7.7 Incident Cases of Metastatic Colorectal Cancer in Spain

17.8 United Kingdom

17.8.1 Incident Cases of Colorectal Cancer in the United Kingdom

17.8.2 Gender-specific Distribution of Colorectal Cancer in the United Kingdom

17.8.3 Age-specific Distribution of Colorectal Cancer in the United Kingdom

17.8.5 Incident Cases of Colorectal Cancer based on Tumor Localization in the United Kingdom

17.8.6 Incident Cases of Colorectal Cancer based on CRC Staging in the United Kingdom

17.8.7 Incident Cases of Metastatic Colorectal Cancer in the United Kingdom

17.9 Japan

17.9.1 Incident Cases of Colorectal Cancer in Japan

17.9.2 Gender-specific Distribution of Colorectal Cancer in Japan

17.9.3 Age-specific Distribution of Colorectal Cancer in Japan

17.9.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Japan

17.9.6 Incident Cases of Colorectal Cancer based on CRC Staging in Japan

17.9.7 Incident Cases of Metastatic Colorectal Cancer in Japan

18 Unmet Needs

19 Marketed Drugs

19.1 Key Competitor

19.2 Braftovi (Encorafenib) + Erbitux (Cetuximab)/ Braftovi + Mektovi: Array Biopharma/ Pfizer

19.2.1 Product Description

19.2.2 Other Developmental Activities

19.2.3 Clinical Development

19.2.4 Safety and Efficacy

19.2.5 Product Profile

19.3 Keytruda (Pembrolizumab) Injection: Merck

19.3.1 Drug Description

19.3.2 Other Developmental Activities

19.3.3 Safety and Efficacy

19.3.4 Product Profile

19.4 Nivolumab (Opdivo) + Ipilimumab (Yervoy): Bristol-myers Squibb

19.4.1 Drug Description

19.4.2 Other Developmental Activities

19.4.3 Safety and Efficacy

19.4.4 Product Profile

19.5 Cyramza (Ramucirumab) Injection + Folfiri: Eli Lilly

19.5.1 Drug Description

19.5.2 Other Developmental Activities

19.5.3 Safety and Efficacy

19.5.4 Product Profile

19.6 Lonsurf: Taiho Oncology

19.6.1 Drug Description

19.6.2 Other Developmental Activities

19.6.3 Safety and Efficacy

19.6.4 Product Profile

19.7 Vectibix (Panitumumab) + Folfox: Amgen

19.7.1 Drug Description

19.7.2 Other Developmental Activities

19.7.3 Safety and Efficacy

19.7.4 Product Profile

20 Emerging Drugs

20.1 Key Competitor

20.2 Napabucasin (BBI-608): Sumitomo Dainippon Pharma

20.2.1 Product Description

20.2.2 Other Developmental Activities

20.2.3 Clinical Development

20.2.4 Safety and Efficacy

20.2.5 Product Profile

20.3 Fruquintinib: Hutchison Medipharma Limited

20.3.1 Product Description

20.3.2 Other Developmental Activities

20.3.3 Clinical Development

20.3.4 Product Profile

20.4 Trilaciclib: G1 Therapeutics

20.4.1 Product Description

20.4.2 Other Developmental Activities

20.4.3 Clinical Development

20.4.4 Product Profile

20.5 Modufolin (Arfolitixorin): Isofol Medical

20.5.1 Product Description

20.5.2 Other Developmental Activities

20.5.3 Clinical Development

20.5.4 Safety and Efficacy

20.5.5 Product Profile

20.6 Olaparib ± Bevacizumab: Merck

20.6.1 Other Developmental Activities

20.6.2 Clinical Development

20.6.3 Product Profile

20.7 Masitinib: AB Science

20.7.1 Product Description

20.7.2 Other Developmental Activities

20.7.3 Clinical Development

20.7.4 Product Profile

20.8 Avelumab + Cetuximab: Merck

20.8.1 Product Description

20.8.2 Other Developmental Activities

20.8.3 Clinical Development

20.8.4 Safety and Efficacy

20.8.5 Product Profile

20.9 Lenvatinib + Pembrolizumab: Merck/Eisai

20.9.1 Product Description

20.9.2 Other Developmental Activities

20.9.3 Clinical Development

20.9.4 Safety and Efficacy

20.9.5 Product Profile

20.10 Tucatinib + Trastuzumab: Merck/Seagen

20.10.1 Product Description

20.10.2 Clinical Development

20.10.3 Safety and Efficacy

20.10.4 Product Profile

20.11 Tomivosertib + Avelumab: Effector Therapeutics

20.11.1 Product Description

20.11.2 Clinical Development

20.11.3 Safety and Efficacy

20.11.4 Product Profile

20.12 Cabozantinib: Exelixis

20.12.1 Product Description

20.12.2 Other Developmental Activities

20.12.3 Clinical Development

20.12.4 Safety and Efficacy

20.12.5 Product Profile

20.13 VXM01: Vaximm

20.13.1 Product Description

20.13.2 Clinical Development

20.13.3 Product Profile

20.14 ENHERTU (DS-8201A): Daiichi Sankyo/Astrazeneca

20.14.1 Product Description

20.14.2 Clinical Development

20.14.3 Safety and Efficacy

20.14.4 Product Profile

20.15 Adagrasib (MRTX849): Mirati Therapeutics

20.15.1 Product Description

20.15.2 Other Developmental Activities

20.15.3 Clinical Development

20.15.4 Safety and Efficacy

20.15.5 Product Profile

20.16 Olaptesed (NOX-A12): Noxxon Pharma

20.16.1 Product Description

20.16.2 Other Developmental Activities

20.16.3 Clinical Development

20.16.4 Safety and Efficacy

20.16.5 Product Profile

20.17 Onvansertib: Cardiff Oncology

20.17.1 Product Description

20.17.2 Other Developmental Activities

20.17.3 Clinical Development

20.17.4 Safety and Efficacy

20.17.5 Product Profile

20.18 Monalizumab: Medimmune

20.18.1 Product Description

20.18.2 Other Developmental Activities

20.18.3 Clinical Development

20.18.4 Safety and Efficacy

20.18.5 Product Profile

21 Market Access And Reimbursement

22 Metastatic Colorectal Cancer (mCRC): Seven Major Market Analysis

22.1 Key Findings

22.2 Market Size Of Metastatic Colorectal Cancer (mCRC) In The 7MM

23 7MM Market Outlook

23.1.1 Prescription Pattern Analysis

23.1.2 Emerging Drugs Analysis

23.2 United States Market Size

23.2.1 Total Market size of Metastatic Colorectal Cancer

23.2.2 Market Size by Therapies in First-line of Treatment

23.2.3 Market Size by Therapies in Second-line of Treatment

23.2.4 Market Size by Therapies in Third-line of Treatment and Above

23.3 EU5 Market Size

23.4 Germany

23.4.1 Total Market size of Metastatic Colorectal Cancer

23.4.2 Market Size by Therapies in First-line of Treatment

23.4.3 Market Size by Therapies in Second-line of Treatment

23.4.4 Market Size by Therapies in Third-line of Treatment and Above

23.5 France

23.5.1 Total Market size of Metastatic Colorectal Cancer

23.5.2 Market Size by Therapies in First-line of Treatment

23.5.3 Market Size by Therapies in Second-line of Treatment

23.5.4 Market Size by Therapies in Third-line of Treatment And Above

23.6 Italy

23.6.1 Total Market size of Metastatic Colorectal Cancer

23.6.2 Market Size by Therapies in First-line of Treatment

23.6.3 Market Size by Therapies in Second-line of Treatment

23.6.4 Market Size by Therapies in Third-line of Treatment And Above

23.7 Spain

23.7.1 Total Market size of Metastatic Colorectal Cancer

23.7.2 Market Size by Therapies in First-line of Treatment

23.7.3 Market Size by Therapies in Second-line of Treatment

23.7.4 Market Size by Therapies in Third-line of Treatment And Above

23.8 United Kingdom

23.8.1 Total Market size of Metastatic Colorectal Cancer

23.8.2 Market Size by Therapies in First-line of Treatment

23.8.3 Market Size by Therapies in Second-line of Treatment

23.8.4 Market Size by Therapies in Third-line of Treatment And Above

23.9 Japan Market Size

23.9.1 Total Market size of Metastatic Colorectal Cancer

23.9.2 Market Size by Therapies in First-line of Treatment

23.9.3 Market Size by Therapies in Second-line of Treatment

23.9.4 Market Size by Therapies in Third-line of Treatment And Above

24 Case Reports

25 Market Drivers

26 Market Barriers

27 SWOT Analysis

28 KOL Views

29 Appendix

29.1 Bibliography

29.2 Report Methodology

30 Delveinsight Capabilities

31 Disclaimer

32 About Delveinsight

Table 1: Summary Of mCRC, Market, Epidemiology And Key Events (2017-2030)

Table 2: AJCC Staging For CRC

Table 3: Prognostic Factors In mCRC

Table 4: Predictive Factors For Targeted Therapies In mCRC

Table 5: The List Of Biomarkers Used In The Clinical Practice Of mCRC

Table 6: Recognized Establishments

Table 7: Percentage Of Patients That Are Prescribed Different Lines Of Treatment For mCRC

Table 8: Recommendations On Symptom Management 

Table 9: Recommendations On Diagnosis 

Table 10: Recommendations On Staging 

Table 11: First-line Treatment

Table 12: Recommendations On Second-line Systemic Colorectal Metastatic Treatment 

Table 13: Recommendations On Third-line And Fourth-line Systemic Colorectal Metastatic Treatment 

Table 14: Recommendations On Liver-directed Therapies In Patients With mCRC 

Table 15: Summary Treatment Options For Late-stage CRC 

Table 16: Recommendations On Surveillance/Follow-up 

Table 17: mCRC: Sign Recommendations

Table 18: mCRC Treatment: Grade Recommendations

Table 19: Evaluation Of Elderly Patients: Sign Recommendations

Table 20: Surgery: Sign Recommendations

Table 21: Liver-directed Therapies: Sign Recommendations

Table 22: Non-liver-directed Therapies: Sign Recommendations

Table 23: Recommendations For Diagnosis And Treatment Of mCRC

Table 24: Incident Population Of Colorectal Cancer In The 7mm (2017-2030)

Table 25: Incident Population Of Metastatic Colorectal Cancer In The 7mm (2017-2030)

Table 26: Incidence Of Colorectal Cancer In The US (2017-2030)

Table 27: Gender-specific Distribution Of Colorectal Cancer In The US (2017-2030)

Table 28: Age-specific Distribution Of Colorectal Cancer In The US (2017-2030)

Table 29: Incident Cases Of Colorectal Cancer Based On Tumor Localization In The US (2017-2030)

Table 30: Incident Cases Of Colorectal Cancer Based On CRC Staging In The US (2017-2030)

Table 31: Incident Cases Of Metastatic Colorectal Cancer In The US (2017-2030)

Table 32: Incident Cases Of Colorectal Cancer In Germany (2017-2030)

Table 33: Gender-specific Distribution Of Colorectal Cancer In Germany (2017-2030)

Table 34: Age-specific Distribution Of Colorectal Cancer In Germany (2017-2030)

Table 35: Incident Cases Of Colorectal Cancer Based On Tumor Localization In Germany (2017-2030)

Table 36: Incident Cases Of Colorectal Cancer Based On CRC Staging In Germany (2017-2030)

Table 37: Incident Cases Of Metastatic Colorectal Cancer In Germany (2017-2030)

Table 38: Incident Cases Of Colorectal Cancer In France (2017-2030)

Table 39: Gender-specific Distribution Of Colorectal Cancer In France (2017-2030)

Table 40: Age-specific Distribution Of Colorectal Cancer In France (2017-2030)

Table 41: Incident Cases Of Colorectal Cancer Based On Tumor Localization In France (2017-2030)

Table 42: Incident Cases Of Colorectal Cancer Based On CRC Staging In France (2017-2030)

Table 43: Incident Cases Of Metastatic Colorectal Cancer In France (2017-2030)

Table 44: Incident Cases Of Colorectal Cancer In Italy (2017-2030)

Table 45: Gender-specific Distribution Of Colorectal Cancer In Italy (2017-2030)

Table 46: Age-specific Distribution Of Colorectal Cancer In Italy (2017-2030)

Table 47: Incident Cases Of Colorectal Cancer Based On Tumor Localization In Italy (2017-2030)

Table 48: Incident Cases Of Colorectal Cancer Based On CRC Staging In Italy (2017-2030)

Table 49: Incident Cases Of Metastatic Colorectal Cancer In Italy (2017-2030)

Table 50: Incident Cases Of Colorectal Cancer In Spain (2017-2030)

Table 51: Gender-specific Distribution Of Colorectal Cancer In Spain (2017-2030)

Table 52: Age-specific Distribution Of Colorectal Cancer In Spain (2017-2030)

Table 53: Incident Cases Of Colorectal Cancer Based On Tumor Localization In Spain (2017-2030)

Table 54: Incident Cases Of Colorectal Cancer Based On CRC Staging In Spain (2017-2030)

Table 55: Incident Cases Of Metastatic Colorectal Cancer In Spain (2017-2030)

Table 56: Incident Cases Of Colorectal Cancer In The UK (2017-2030)

Table 57: Gender-specific Distribution Of Colorectal Cancer In The UK (2017-2030)

Table 58: Age-specific Distribution Of Colorectal Cancer In The UK (2017-2030)

Table 59: Incident Cases Of Colorectal Cancer Based On Tumor Localization In The UK (2017-2030)

Table 60: Incident Cases Of Colorectal Cancer Based On CRC Staging In The UK (2017-2030)

Table 61: Incident Cases Of Metastatic Colorectal Cancer In The UK (2017-2030)

Table 62: Incident Cases Of Colorectal Cancer In Japan (2017-2030)

Table 63: Gender-specific Distribution Of Colorectal Cancer In Japan (2017-2030)

Table 64: Age-specific Distribution Of Colorectal Cancer In Japan (2017-2030)

Table 65: Incident Cases Of Colorectal Cancer Based On Tumor Localization In Japan (2017-2030)

Table 66: Incident Cases Of Colorectal Cancer Based On CRC Staging In Japan (2017-2030)

Table 67: Incident Cases Of Metastatic Colorectal Cancer In Japan (2017-2030)

Table 68: Comparison Of Marketed Drugs

Table 69: Patent Expiration

Table 70: Braftovi + Mektovi + Erbitux, Clinical Trial Description, 2020

Table 71: Patent Expiration

Table 72: Patent Expiration

Table 73: Patent Expiration

Table 74: Patent Expiration

Table 75: Patent Expiration

Table 76: Comparison Of Emerging Drugs Under Development

Table 77: Napabucasin, Clinical Trial Description, 2020

Table 78: Fruquintinib, Clinical Trial Description, 2020

Table 79: Patent Expiration

Table 80: Trilaciclib, Clinical Trial Description, 2020

Table 81: Patent Expiration

Table 82: Arfolitixorin, Clinical Trial Description, 2020

Table 83: Patent Expiration

Table 84: Olaparib ± Bevacizumab, Clinical Trial Description, 2020

Table 85: Patent Expiration

Table 86: Masitinib, Clinical Trial Description, 2020

Table 87: Avelumab + Cetuximab, Clinical Trial Description, 2020

Table 88: Patent Expiration

Table 89: Lenvatinib + Pembrolizumab, Clinical Trial Description, 2020

Table 90: Trastuzumab + Tucatinib, Clinical Trial Description, 2020

Table 91: Tomivosertib + Avelumab, Clinical Trial Description, 2020

Table 92: Cabozantinib, Clinical Trial Description, 2020

Table 93: VXM01, Clinical Trial Description, 2020

Table 94: Enhertu, Clinical Trial Description, 2020

Table 95: Adagrasib, Clinical Trial Description, 2020

Table 96: Olaptesed, Clinical Trial Description, 2020

Table 97: Patent Expiration

Table 98: Onvansertib, Clinical Trial Description, 2020

Table 99: Patent Expiration

Table 100: Monalizumab, Clinical Trial Description, 2020

Table 101: Seven Major Market Size Of mCRC In USD Million (2017-2030)

Table 102: Launch Dates Of Potential Emerging Drugs

Table 103: Total Market Size Of mCRC In The US, In USD Million (2017-2030)

Table 104: Market Size Of mCRC By Therapies In 1st Lot In The US, In USD Million (2017-2030)

Table 105: Market Size Of mCRC By Therapies In 2nd Lot In The US, In USD Million (2017-2030)

Table 106: Market Size Of mCRC By Therapies In 3rd Lot+ In The US, In USD Million (2017-2030)

Table 107: Total Market Size Of mCRC In Germany, In USD Million (2017-2030)

Table 108: Market Size Of mCRC By Therapies In 1st Lot In Germany, In USD Million (2017-2030)

Table 109: Market Size Of mCRC By Therapies In 2nd Lot In Germany, In USD Million (2017-2030)

Table 110: Market Size Of mCRC By Therapies In 3rd Lot+ In Germany, In USD Million (2017-2030)

Table 111: Total Market Size Of mCRC In France, In USD Million (2017-2030)

Table 112: Market Size Of mCRC By Therapies In 1st Lot In France, In USD Million (2017-2030)

Table 113: Market Size Of mCRC By Therapies In 2nd Lot In France, In USD Million (2017-2030)

Table 114: Market Size Of mCRC By Therapies In 3rd Lot+ In France, In USD Million (2017-2030)

Table 115: Total Market Size Of mCRC In Italy, In USD Million (2017-2030)

Table 116: Market Size Of mCRC By Therapies In 1st Lot In Italy, In USD Million (2017-2030)

Table 117: Market Size Of mCRC By Therapies In 2nd Lot In Italy, In USD Million (2017-2030)

Table 118: Market Size Of mCRC By Therapies In 3rd Lot+ In Italy, In USD Million (2017-2030)

Table 119: Total Market Size Of mCRC In Spain, In USD Million (2017-2030)

Table 120: Market Size Of mCRC By Therapies In 1st Lot In Spain, In USD Million (2017-2030)

Table 121: Market Size Of mCRC By Therapies In 2nd Lot In Spain, In USD Million (2017-2030)

Table 122: Market Size Of mCRC By Therapies In 3rd Lot+ In Spain, In USD Million (2017-2030)

Table 123: Total Market Size Of mCRC In The UK, In USD Million (2017-2030)

Table 124: Market Size Of mCRC By Therapies In 1st Lot In The UK, In USD Million (2017-2030)

Table 125: Market Size Of mCRC By Therapies In 2nd Lot In The UK, In USD Million (2017-2030)

Table 126: Market Size Of mCRC By Therapies In 3rd Lot+ In The UK, In USD Million (2017-2030)

Table 127: Total Market Size Of mCRC In Japan, In USD Million (2017-2030)

Table 128: Market Size Of mCRC By Therapies In 1st Lot In Japan, In USD Million (2017-2030)

Table 129: Market Size Of mCRC By Therapies In 2nd Lot In Japan, In USD Million (2017-2030)

Table 130: Market Size Of mCRC By Therapies In 3rd Lot+ In Japan, In USD Million (2017-2030)

Figure 1: Mechanisms of Metastasis in CRC- Hematogenous Versus Peritoneal Spread.

Figure 2: Current And Emerging Biomarkers Used in Personalizing Treatment For Patients With mCRC

Figure 3: EGFR Signaling Pathway With Potential Predictive Markers

Figure 4: VEGF Signaling Pathway

Figure 5: NCCN Guidelines For Colon Cancer

Figure 6: NCCN Guidelines For the Treatment of Rectal Cancer

Figure 7: Zurich Treatment Algorithm

Figure 8: Incident Population of Colorectal Cancer in the 7MM (2017–2030)

Figure 9: Incident Population of Metastatic Colorectal Cancer in the 7MM (2017–2030)

Figure 10: Incident Cases of Colorectal Cancer in the US (2017–2030)

Figure 11: Gender-specific Distribution of Colorectal Cancer in the US (2017–2030)

Figure 12: Age-specific Distribution of Colorectal Cancer in the US (2017–2030)

Figure 13: Incident Cases of Colorectal Cancer Based On Tumor Localization in the US (2017–2030)

Figure 14: Incident Cases of Colorectal Cancer Based On CRC Staging In the US (2017–2030)

Figure 15: Incident Cases of Metastatic Colorectal Cancer in the US (2017–2030)

Figure 16: Incident Cases of Colorectal Cancer in Germany (2017–2030)

Figure 17: Gender-specific Distribution of Colorectal Cancer in Germany (2017–2030)

Figure 18: Age-specific Distribution of Colorectal Cancer in Germany (2017–2030)

Figure 19: Incident Cases of Colorectal Cancer Based On Tumor Localization in Germany (2017–2030)

Figure 20: Incident Cases of Colorectal Cancer Based On CRC Staging in Germany (2017–2030)

Figure 21: Incident Cases of Metastatic Colorectal Cancer in Germany (2017–2030)

Figure 22: Incident Cases of Colorectal Cancer in France (2017–2030)

Figure 23: Gender-specific Distribution of Colorectal Cancer in France (2017–2030)

Figure 24: Age-specific Distribution of Colorectal Cancer in France (2017–2030)

Figure 25: Incident Cases of Colorectal Cancer Based On Tumor Localization in France (2017–2030)

Figure 26: Incident Cases of Colorectal Cancer Based On CRC Staging in France (2017–2030)

Figure 27: Incident Cases of Metastatic Colorectal Cancer in France (2017–2030)

Figure 28: Incident Cases of Colorectal Cancer in Italy (2017–2030)

Figure 29: Gender-specific Distribution of Colorectal Cancer in Italy (2017–2030)

Figure 30: Age-specific Distribution of Colorectal Cancer in Italy (2017–2030)

Figure 31: Incident Cases of Colorectal Cancer Based On Tumor Localization in Italy (2017–2030)

Figure 32: Incident Cases of Colorectal Cancer Based On CRC Staging in Italy (2017–2030)

Figure 33: Incident Cases of Metastatic Colorectal Cancer in Italy (2017–2030)

Figure 34: Incident Cases of Colorectal Cancer in Spain (2017–2030)

Figure 35: Gender-specific Distribution of Colorectal Cancer in Spain (2017–2030)in

Figure 36: Age-specific Distribution of Colorectal Cancer in Spain (2017–2030)

Figure 37: Incident Cases of Colorectal Cancer Based On Tumor Localization in Spain (2017–2030)

Figure 38: Incident Cases of Colorectal Cancer Based On CRC Staging in Spain (2017–2030)

Figure 39: Incident Cases of Metastatic Colorectal Cancer in Spain (2017–2030)

Figure 40: Incident Cases of Colorectal Cancer in the UK (2017–2030)

Figure 41: Gender-specific Distribution of Colorectal Cancer in the UK (2017–2030)

Figure 42: Age-specific Distribution of Colorectal Cancer in the UK (2017–2030)

Figure 43: Incident Cases of Colorectal Cancer Based On Tumor Localization in the UK (2017–2030)

Figure 44: Incident Cases of Colorectal Cancer Based On CRC Staging in the UK (2017–2030)

Figure 45: Incident Cases of Metastatic Colorectal Cancer in the UK (2017–2030)

Figure 46: Incident Cases of Colorectal Cancer in Japan (2017–2030)

Figure 47: Gender-specific Distribution of Colorectal Cancer in Japan (2017–2030)

Figure 48: Age-specific Distribution of Colorectal Cancer in Japan (2017–2030)

Figure 49: Incident Cases of Colorectal Cancer Based On Tumor Localization in Japan (2017–2030)

Figure 50: Incident Cases of Colorectal Cancer Based On CRC Staging In Japan (2017–2030)

Figure 51: Incident Cases of Metastatic Colorectal Cancer in Japan (2017–2030)

Figure 52: Unmet Needs of mCRC

Figure 53: Seven Major Market Size of mCRC in USD Million (2017–2030)

Figure 54: Total Market Size of mCRC in the US, USD Millions (2017–2030)

Figure 55: Market Size of mCRC by Therapies in 1st Lot in the US, in USD Million (2017–2030)

Figure 56: Market Size of mCRC by Therapies in 2nd Lot in the US, in USD Million (2017–2030)

Figure 57: Market Size of mCRC by Therapies in 3rd Lot+ in the US, in USD Million (2017–2030)

Figure 58: Total Market Size of mCRC in Germany, USD Millions (2017–2030)

Figure 59: Market Size of mCRC by Therapies in 1st Lot in Germany, in USD Million (2017–2030)

Figure 60: Market Size of mCRC by Therapies in 2nd Lot in Germany, in USD Million (2017–2030)

Figure 61: Market Size of mCRC by Therapies in 3rd Lot+ in Germany, in USD Million (2017–2030)

Figure 62: Total Market Size of mCRC in France, USD Millions (2017–2030)

Figure 63: Market Size of mCRC by Therapies in 1st Lot in France, in USD Million (2017–2030)

Figure 64: Market Size of mCRC by Therapies in 2nd Lot in France, in USD Million (2017–2030)

Figure 65: Market Size of mCRC by Therapies in 3rd Lot+ in France, in USD Million (2017–2030)

Figure 66: Total Market Size of mCRC in Italy, USD Millions (2017–2030)

Figure 67: Market Size of mCRC by Therapies in 1st Lot in Italy, in USD Million (2017–2030)

Figure 68: Market Size of mCRC by Therapies in 2nd Lot in Italy, in USD Million (2017–2030)

Figure 69: Market Size of mCRC by Therapies in 3rd Lot+ in Italy, in USD Million (2017–2030)

Figure 70: Total Market Size of mCRC in Spain, USD Millions (2017–2030)

Figure 71: Market Size of mCRC by Therapies in 1st Lot in Spain, in USD Million (2017–2030)

Figure 72: Market Size of mCRC by Therapies in 2nd Lot in Spain, in USD Million (2017–2030)

Figure 73: Market Size of mCRC by Therapies in 3rd Lot+ in Spain, in USD Million (2017–2030)

Figure 74: Total Market Size of mCRC in the UK, USD Millions (2017–2030)

Figure 75: Market Size of mCRC by Therapies in 1st Lot in the UK, in USD Million (2017–2030)

Figure 76: Market Size of mCRC by Therapies in 2nd Lot in the UK, in USD Million (2017–2030)

Figure 77: Market Size of mCRC by Therapies in 3rd Lot+ in the UK, in USD Million (2017–2030)

Figure 78: Total Market Size of mCRC in Japan, USD Millions (2017–2030)

Figure 79: Market Size of mCRC by Therapies in 1st Lot in Japan, in USD Million (2017–2030)

Figure 80: Market Size of mCRC by Therapies in 2nd Lot Japan, in USD Million (2017–2030)

Figure 81: Market Size of mCRC by Therapies in 3rd Lot+ in Japan, in USD Million (2017–2030)

Figure 82: Market Drivers

Figure 83: Market Barriers

Figure 84: SWOT Analysis of mCRC

Array Biopharma/ Pfizer

Merck

Bristol-Myers Squibb

Eli Lilly

Taiho Oncology

Amgen

Sumitomo Dainippon Pharma

Hutchison Medipharma Limited

G1 Therapeutics

Isofol Medical

Merck

Ab Science

Merck

Merck/Eisai

Merck/Seagen

Effector Therapeutics

Exelixis

Vaximm

Daiichi Sankyo/Astrazeneca

Mirati Therapeutics

Noxxon Pharma

Cardiff Oncology

Medimmune

  • Tags:
  • Metastatic Colorectal Cancer market
  • Metastatic Colorectal Cancer market...
  • Metastatic Colorectal Cancer market...
  • Metastatic Colorectal Cancer market...
  • Metastatic Colorectal Cancer market...
  • Metastatic Colorectal Cancer market...
  • Metastatic Colorectal Cancer pipeli...
  • Metastatic Colorectal Cancer treatm...
  • Metastatic Colorectal Cancer drugs
  • Metastatic Colorectal Cancer sales...
  • Metastatic Colorectal Cancer market...
  • Metastatic Colorectal Cancer diseas...
  • Metastatic Colorectal Cancer epidem...
  • Metastatic Colorectal Cancer

Forward to Friend

Need A Quote